Under the deal, Teva will receive exclusive global rights to develop, manufacture and commercialise new CGRP antagonists discovered by Heptares.
The deal will see Heptares receive an upfront payment of $10m, research funding, and is eligible to receive additional research, development and commercialisation milestone payments of up to $400m.
In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the agreement.
Teva Global R&D president and chief scientific officer Michael Hayden said: “We are delighted to begin this partnership with Heptares, which through its industry-leading, structure-based design approach has generated novel CGRP antagonists with significant promise for treating migraine.
“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody.”
CGRP is released during migraine attacks and can trigger migraine in patients, while it is found in small to medium-sized neurons in the trigeminal ganglion and mediates its activity through G protein-coupled receptors located throughout the body.
Increased levels of CGRP are found in migraineurs during an attack and blocking CGRP activity is a validated mechanism of action for relieving pain as well to prevent migraine.
Heptares chief executive officer Malcolm Weir said: “This agreement is an exciting development for our CGRP antagonist programme.
“Teva brings world-leading clinical and commercial expertise in migraine to advance this programme based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising programme.”